ºÚÁÏÍø

Abstract

Kuroiwa acquired his Ph.D. in molecular genetics from Tokyo Institute of Technology, Japan, studying genomic imprinting in mammals. Right after his Ph.D. work, he joined KIRIN Brewery, CO. LTD., to develop its original chromosome engineering technology and contributed to generation of transgenic mice producing human antibodies for human therapy. This achievement was highly recognized and he moved to US to join Hematech Inc to lead a project of transgenic cattle producing human polyclonal antibodies to treat a wide variety of human diseases, as a Research Director of Molecular Genetics department. He established an efficient genetic modification system in cattle and produced the world�s first transchromosomic and knockout cattle. As of July 1st in 2009, he became a Chief Scientific Officer (CSO) of Research division in Hematech.

Biography